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Abstract 
Background: Mortality in individuals with diabetes with severe hypoglycemia requiring ambulance services inter‑
vention is high and it is unclear whether this is modifiable. Our aim was to characterise this high‑risk group and assess 
the impact of nurse‑led intervention on mortality.
Methods: In this single centre study, patients with diabetes and hypoglycemia requiring ambulance call out were 
randomized to nurse led support (intensive arm) or managed using existing pathways (standard arm). A third group 
agreed to have their data collected longitudinally (observational arm). The primary outcome was all‑cause mortality 
comparing intensive with combined standard and observational arms as well as standard arm alone.
Results: Of 828 individuals identified, 323 agreed to participate with 132 assigned to intensive, 130 to standard and 
61 to observational arms. Mean follow up period was 42.6 ± 15.6 months. Mortality in type 1 diabetes (n = 158) was 
similar across study arms but in type 2 diabetes (n = 160) this was reduced to 33% in the intensive arm compared 
with 51% in the combined arm (p = 0.025) and 50% in the standard arm (p = 0.06). Cardiovascular deaths, the leading 
cause of mortality, was lower in the intensive arm compared with combined and standard study arms (p < 0.01).
Conclusions: Medium‑term mortality following severe hypoglycemia requiring the assistance of emergency services 
is high in those with type 2 diabetes. In individuals with type 2 diabetes, nurse‑led individualized intervention reduces 
cardiovascular mortality compared with standard care. Large‑scale multicentre studies are warranted to further inves‑
tigate this approach.
Trial registration The trial was retrospectively registered on http://www.clini caltr ials.gov with reference NCT04422145
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Background
There are two main forms of diabetes mellitus, type 1, 
whereby autoimmune destruction of islet β-cells renders 
the patient insulin deficient and type 2, largely medi-
ated by insulin resistance and later relative insulin defi-
ciency [1, 2].
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Lowering glucose levels has been shown to reduce 
microvascular complications and long-term macrovas-
cular disease in individuals with diabetes  [3–8]. How-
ever, intensive glycemic control increases the risk of 
hypoglycemia, which is associated with adverse clini-
cal outcome  [9–12]. The ACCORD trial demonstrated 
excessive mortality in the intensive glucose arm of 
the study, necessitating study termination and fuel-
ling speculation about the role of tight glucose con-
trol in the management of type 2 diabetes  [13]. While 
subsequent analysis failed to conclusively demonstrate 
that low glucose levels caused the higher mortality in 
intensively-treated patients, hypoglycemia was gener-
ally associated with increased mortality in the study 
population  [14]. There are mechanistic pathways that 
link hypoglycemia to increased mortality, including 
cardiac arrhythmias in the short term and an inflam-
matory-thrombotic response that predisposes to vas-
cular events in the long-term  [15–17]. In particular, a 
study in type 2 diabetes subjects has shown that low 
blood glucose levels, under controlled conditions, 
increases thrombosis risk for up to 1  week, providing 
one explanation for the relationship between cardiovas-
cular death and hypoglycemia  [16]. Indeed, large scale 
studies and anecdotal reports have shown associations 
between antecedent hypoglycemia and vascular mor-
tality [12, 18−21].
In large population studies, the association between 
HbA1c and mortality has been repeatedly shown to take 
a U-shaped curve, raising the possibility that aggressive 
glycemic control increases mortality through precipita-
tion of hypoglycemia  [22, 23]. On the other hand, indi-
viduals with high HbA1c are not necessarily protected 
from severe hypoglycemia  [24], and therefore HbA1c 
levels are not the sole predictors of predisposition to low 
glucose levels.
Our previous work has shown that individuals with 
severe hypoglycemia requiring ambulance services inter-
vention are at high risk of mortality within the 1st  year 
of the event  [25]. However, the main causes of death in 
these individuals were unclear and the longer-term mor-
tality, beyond 1 year, is yet to be established. More impor-
tantly, it is unknown whether the high mortality in this 
population is modifiable and studies in this area have not 
been conducted to date.
We hypothesise that a pragmatic nurse-led inter-
vention reduces mortality in individuals with diabetes 
requiring ambulance services intervention. Therefore, we 
conducted a single centre pilot study with the following 
objectives:
1. Characterise in detail the cohort of patients having 
severe hypoglycemia requiring emergency services 
intervention, study mortality over a long follow up 
period and ascertain the cause of death.
2. Study the effects of structured nurse-led interven-
tion, including patient education, on mortality in this 
population.
Methods
Study participants
Study participants were individuals with diabetes who 
experienced severe hypoglycemia requiring ambu-
lance services call-out in the area in and around the 
city of Leeds, UK. For this work, “severe hypoglycemia” 
was defined as low glucose levels requiring assistance 
of emergency services and not only the help of another 
person as the term is commonly used. Inclusion criteria 
included the presence of any type of diabetes together 
with a recent ambulance call out for severe hypoglyce-
mia. The only exclusion criterion was individuals without 
diabetes.
Enrolment on clinical trials database
The study is enrolled on www.clini caltr ials.gov with ref-
erence number NCT04422145.
Study procedure
Participants were asked to participate in the interven-
tional study but given the option for enrolment in an 
observational study. Therefore, the study comprised 
interventional and observational parts with the first 
divided further into intensive and standard arms as 
follows:
• Interventional study: participants were randomized 
to either:
 • Intensive arm: participants received intensive 
nurse-led intervention for a period of 3 months 
with access to the nurse for a total of 12 months.
• Standard arm: participants were managed accord-
ing to local guidelines.
• Observational study: participants did not want to 
be randomized to receive the intervention but were 
willing to have their records reviewed electronically. 
They were returned to their standard diabetes care 
provider at baseline and not followed up in person by 
the diabetes research nurse.
Participants in the standard and observational arms 
of the trial therefore received the same medical care for 
their diabetes.
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Routine blood tests were conducted in participants 
at baseline, unless blood tests were available within 3 
months prior to enrolment. Blood tests were also taken 
at 6 and 12 months in the intensive arm whilst in those 
in the standard arm or the observational study, the 
electronic records were accessed for routine blood test 
results. Participants were subdivided into type 1 and 2 
diabetes based on data from patient electronic records. 
Figure 1 displays trial design.
Randomization and blinding
Participants in the interventional trial were sequentially 
randomized to receive either intensive nurse led inter-
vention or standard care based on the date they were 
referred to the research team. Given the fact that the 
research nurse was providing education to participants, 
they could not be blinded to study group. The primary 
investigator (RA) was asked for advice only when pat-
terns of glycemia were deemed to be clinically serious, 
including sustained hypoglycemia, nocturnal hypogly-
cemia and consistently high glucose levels (> 240  mg/
dL), consistent with local practice. Investigators aware of 
participants allocation to study arms were not involved in 
data analysis.
Role of the research nurse and structured education 
provided
Following recruitment to the study and randomization to 
the intensive education group, participants received the 
following structured interventions from a senior diabetes 
research nurse:
Fig. 1 A diagrammatic depiction of trial design. Out of 828 diabetes patients suffering severe hypoglycemia, 323 agreed to participate in the study. 
A total of 61 participants did not wish to be involved in an interventional study and were entered into an observational arm. The remaining 262 
participants were randomized to structured nurse led intervention or standard care
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1. An attempt was made to ascertain the likely cause of 
the index episode of hypoglycemia.
2. Written and verbal information was provided regard-
ing common causes of hypoglycemia including exer-
cise, alcohol consumption and anti-diabetic thera-
pies.
3. Participants using insulin were examined for lipohy-
pertrophy and advised on the importance of avoiding 
injection into these sites.
4. Participants were provided with suitable equipment 
to measure their capillary blood glucose if they were 
not already doing so. They were encouraged to meas-
ure glucose at least twice daily and record results for 
later review.
5. A dedicated phone number was provided along with 
an email address for participants to contact the dia-
betes research team with any clinical queries they 
may have.
Following baseline assessment, participants were con-
tacted weekly for the 1st  month after enrolment, every 
2 weeks for the 2nd month and once in the 3rd month. 
Two further contacts occurred at 6 and 12 months and 
therefore main study intervention occurred in the first 3 
months of enrolment. Participants could also contact the 
research team on an ad-hoc basis. During the contacts 
outlined above, the research nurse provided the following 
interventions:
1. Review of capillary blood glucose results and adjust-
ment of medications and insulin doses as neces-
sary. Seeking advice from a diabetologist (RA) only 
occurred in difficult cases or if a prescription of a 
new hypoglycemic agent was deemed necessary (as 
per local guidelines). Therefore, most management 
decisions were made by the study nurse.
2. Further education as required regarding any of the 
topics discussed at the baseline assessment.
Follow up period
All study participants were followed up for a minimum 
period of 12 months. When the study terminated, all 
participants again had their electronic records reviewed 
for mortality. If they were deceased, their cause of death 
was determined by reviewing death certificate of the par-
ticipant, which are issued for all deceased individuals in 
the UK. In UK death certificate, the clinical condition 
directly related to mortality is recorded as the main cause 
of death (which was collected in this study) and contrib-
uting conditions are also highlighted. Cause of death is 
determined by a senior hospital doctor, or primary care 
physician, who is familiar with the patient. Data from 
death certificates are used on a population basis to deter-
mine national health policies.
Endpoints
The primary endpoint was death from any cause at study 
end comparing the intensive study arm with combined 
standard and observational arms as well as the standard 
arm alone.
Secondary and exploratory endpoints included:
• Analyse mortality at 12 months in the whole popu-
lation and separately for type 1 and type 2 diabetes 
individuals.
• Establish the cause of death and study differences 
between study arms.
• Analyse the relationship between baseline HbA1c 
and mortality.
Statistical analysis and power calculations
Given our previous study  [25], our initial power calcu-
lations were based on a follow up of 1  year only, which 
would have required 200 individuals in each group to 
show a drop in mortality from 18–10% secondary to the 
intervention (power of 80%, at p < 0.05). However, given 
the slower than anticipated recruitment rate, the study 
was subsequently revised to extend the follow-up period. 
Assuming a mortality rate of 30% during the extended 
follow up in individuals managed using existing hypogly-
cemic pathways, 106 individuals in each study arm were 
required to demonstrate a reduction in mortality to 15% 
in the intensive arm of the study with a power of 80% (at 
p < 0.05). Assuming a drop-out rate of 20%, we aimed 
to recruit a minimum of 130 individuals in each of the 
intensive and standard study arms.
Minitab v.19 (Mintab, inc, USA) was used for statistical 
analysis. Kaplan–Meier survival curves were made using 
Prism v8.3.1 (Graphpad, USA). Chi-squared test was 
used for testing proportions, while T-test was employed 
to analyse normally distributed continuous variables 
between two groups. When numbers of participants with 
a particular outcome for a categorical variable was small 
(≤ 5 in any category), Fishers exact test was used. For 
testing differences in baseline characteristics between the 
three groups, one-way ANOVA was used for continuous 
variables and Chi-squared for categorical variables. For 
all analysis, an intention to treat methodology was used 
with all participants being analysed according to their 
original group, independent of drop out.
Given that individuals in the standard arm and the 
observational study received the same care, namely 
their diabetes was managed by their standard healthcare 
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provider following the episode of hypoglycemia, data was 
analysed in two ways:
1. Comparison between the intensive arm and the com-
bined standard arm/observational study (termed 
combined group).
2. Comparison of the intensive and standard arms of 
the interventional study.
Results
Recruitment rate
A total of 828 referals to the study team were made by 
ambulance services, of which 98 involved referrals of the 
same participant more than once. After discounting these 
732 prospective particpants were left. Of these, 232 of 
declined involvement at an initial screening phone call, 
84 could not be contacted, 55 could not provide written 
informed consent, 48 did not attend a planned meeting 
with the research team, 3 died prior to contact and 1 was 
not contacted in error by the research team. This left 323 
participants of whom 61 agreed to be followed up remotely 
but did not wish to be randomized to the interventional 
trial (observational group) and 262 participants whom were 
randomized to standard care or intensive intervention.
The first participant was recruited to the trial in Febru-
ary 2013 and the last participant was recruited in Decem-
ber 2017. The study was terminated after reaching the 
required numbers in the interventional arm together with 
a minimum follow up of 12 months (December 2018).
Baseline characteristics
A total of 262 participants agreed to participate in the 
interventional study with an additional 61 participants 
participating in the observational study. Across all 
groups, 158 participants had type 1 diabetes (48.9%), 160 
participants had type 2 diabetes (49.5%) and 5 partici-
pants (1.5%) had other forms of diabetes.
A summary of baseline characteristics is shown in 
Table 1. 
In the interventional part of the study, no statistical dif-
ferences were observed in any variable when comparing 
the intervention and standard groups alone.
Follow up period
Follow up periods (months) were 41.0 ± 16.2, 40.6 ± 16.2 
and 50.2 ± 10.0 for interventional, standard and observa-
tional groups respectively.
Mortality
In total, across all 3 groups, there were 90 deaths 
(27.9%) of whom 30 died in the first 12 months follow-
ing ambulance call out (9.3%).
Comparing the intensive and combined arms, 28 
(21.2%) and 62 (32.4%) deaths occurred respectively, 
during study period (p = 0.022). The risk ratio (RR) for 
all-cause mortality comparing intensive and combined 
arms was 0.65 (95% CI 0.44–0.96). A similar pattern 
was seen, albeit non–significant, comparing intensive 
to standard study arms of the interventional study, 28 
(21.2%) and 39 (30.0%), respectively, p = 0.10) with RR 
for all-cause mortality of 0.71 (0.46–1.08).
When type 1 and type 2 diabetes individuals were 
separately analysed, a clear difference was demon-
strated. In individuals with type 1 diabetes, mortal-
ity in the intensive arm at 11.6% was similar to those 
receiving standard management, regardless whether it 
was analysed as a combined group (mortality 12.4%) or 
when compared with the standard arm of the interven-
tional study (mortality 10.8%). In individuals with type 
2 diabetes, mortality in the intensive arm was lower 
at 33.3% than the combined group (51.2%; p = 0.025) 
with a similar trend observed when compared with 
the standard arm of the interventional study (50.0%; 
p = 0.06).
Kaplan Meier survival curves show mortality for all 
three groups when analysed as a whole group (Fig. 2a), 
for those with type 1 diabetes (Fig. 2b) and those with 
type 2 diabetes (Fig. 2c).
Cause of death
The leading cause of death overall was cardiovascu-
lar disease (30% of cases) with rates of this outcome 
being significantly lower in the intensive arm of the 
interventional study (2.3% of participants) compared 
to standard and combined groups (10.8% and 13.1%, 
respectively p < 0.05).
Cause of death in type 1 diabetes
Overall, mortality in participants with type 1 diabetes 
during study follow up was 12% and showed no differ-
ence between the groups (detailed above). Cause of death 
was similar across study groups with no trend identified. 
Of note, both of the deaths attributed directly to a glyce-
mic emergency were seen in those with type 1 diabetes 
(one in intensive and one in standard study arms).
Mean age of death was 62.7 ± 14.9  years and mean 
time between enrolment to study and death was 
26.2 ± 19.7 months.
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Table 1 A summary of baseline patient characteristics
Data are presented as number (%) or mean ± SD
Numbers in italics signify statistically significant differences
Intensive (n = 132) Standard (n = 130) Observational 
(n = 61)
Difference 
between groups
Ethnicity (%) White 116 (87.9) 107 (82.3) 58 (95.1)
Afro‑Caribbean 5 (3.8) 11 (8.5) 0
South Asian 9 (6.8) 9 (6.9) 1 (1.6)
Other 2 (1.5) 3 (2.3) 2 (3.3)
Form of diabetes (%) Type 1 diabetes 69 (52.3) 65 (50) 24 (39.3) p = 0.24
Type 2 diabetes 60 (45.4) 64 (49.2) 36 (59) p = 0.22
Other diabetes 3 (2.3) 1 (0.8) 1 (1.6) NA
Male gender (%) Total 83 (62) 76 (58.5) 35 (57.4) p = 0.68
T1D 48 (69.6) 38 (58.5) 16 (66.7) p = 0.40
T2D 33 (55) 37 (57.8) 18 (50) p = 0.75
Age (years ± SD) Total 61.4 ± 1 8.5 62.0 ± 18.7 70.3 ± 14.0 p = 0.03
T1D 50.5 ± 16.7 49.7 ± 16.5 59.7 ± 12.9 p = 0.03
T2D 74.2 ± 10.7 74.84 ± 10.2 77.3 ± 9.8 p = 0.38
Presenting capillary glucose (mmol/L ± SD) Total 2.1 ± 0.7 2.2 ± 1.0 2.1 ± 0.6 p = 0.79
T1D 2.0 ± 0.7 2.1 ± 1.2 1.9 ± 0.6 p = 0.73
T2D 2.3 ± 0.7 2.3 ± 0.8 2.3 ± 0.6 p = 0.94
HbA1c (mmol/mol ± SD) Total 62.8 ± 17.1 63.5 ± 15.6 60.8 ± 17.0 p = 0.62
T1D 66.3 ± 19.4 66.8 ± 14.5 61.3 ± 10.5 p = 0.40
T2D 58.5 ± 13.4 60.0 ± 16.2 61.2 ± 20.4 p = 0.76
Current smoker (%) Total 29 (22.0) 27 (20.8) 10 (16.4) p = 0.66
T1D 22 (31.9) 18 (27.7) 5 (20.8) p = 0.45
T2D 7 (11.7) 9 (14.0) 5 (13.9) p = 0.91
Duration of diabetes (years ± SD) Total 23.7 ± 14.0 23.1 ± 12.7 25.7 ± 13.7 p = 0.58
T1D 26.3 ± 15.6 27.2 ± 13.1 32.0 ± 12.0 p = 0.25
T2D 21.0 ± 11.3 19.3 ± 10.7 20.9 ± 3.3 p = 0.67
BMI (kg/m2 ± SD) Total 28.6 ± 7.4 27. 9 ± 6.8 27.1 ± 5.6 p = 0.43
T1D 26.9 ± 7.4 26.6 ± 7.4 25.6 ± 3.4 p = 0.75
T2D 31.0 ± 7.7 29.5 ± 5.8 28.1 ± 6.7 p = 0.18
Established cardiovascular disease (%) Total 35 (26.5) 43 (33.1) 26 (42.6) p = 0.08
T1D 13 (18.8) 13 (20) 8 (33.3) p = 0.31
T2D 21 (35) 30 (46.9) 18 (50) p = 0.26
Antiplatelet use (%) Total 48 (36.4) 49 (37.7) 28 (45.9) p = 0.43
T1D 17 (24.6) 20 (30.1) 9 (37.5) p = 0.46
T2D 88 (66.7) 29 (45.3) 19 (52.8) p = 0.75
Lipid lowering therapy use (%) Total 30 (50) 84 (64.6) 42 (68.9) p = 0.84
T1D 36 (52.2) 37 (56.9) 17 (70.8) p = 0.28
T2D 50 (83.3) 47 (73.4) 24 (66.7) p = 0.16
Anti‑hypertensive use (%) Total 81 (61.4) 83 (63.8) 41 (67.2) p = 0.73
T1D 30 (43.4) 30 (46.2) 17 (70.8) p = 0.06
T2D 50 (83.3) 53 (82.8) 23 (63.9) p = 0.05
Type 2 diabetes receiving insulin (%) 48 (80) 53 (82.8) 26 (72.2) p = 0.45
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Of note, those with type 1 diabetes in the study were 
younger and less likely to have established CV dis-
ease when compared to their counterparts with type 2 
diabetes.
Cause of death in type 2 diabetes
Mortality in type 2 diabetes was much higher (44.3% 
across all groups) and in contrast to type 1 diabetes, 
showed differences between study arms. Cardiovascular 
disease was the leading cause of death in those with type 
2 diabetes followed by infection. There was a significant 
reduction in death from a cardiovascular cause when 
comparing those in the intensive arm to those in the 
combined or standard groups (p < 0.01 for both). A sepa-
rate analysis was conducted on those without clinically 
established CV disease to understand the role of inter-
vention in this subgroup. A numerical decrease in mor-
tality was evident in the interventional compared with 
the standard arm and while this failed to reach statistical 
significance, it was consistent with overall study findings 
(mortality at 28.2% and 41.0%, respectively; p = 0.24). 
Moreover, there was a statistically significant difference 
in rates of CV death comparing interventional and stand-
ard arms in this subgroup of individuals (0% vs. 14.7%, 
respectively; p = 0.01).
When further analysing the main cause of cardiovas-
cular death in those with type 2 diabetes, we determined 
whether this was due to a cardiac, cerebrovascular or 
peripheral vascular cause. For the interventional group, 
the lone cardiovascular death was caused by coro-
nary artery disease. For the standard group, 10 par-
ticipants had a cardiac cause listed as the main cause of 
death, while in two participants cerebrovascular disease 
resulted in death. For the observational group, the main 
cause of death was cardiac in nine participants, cerebro-
vascular in one participant and peripheral vascular in one 
participant.
Mean age at death was 78.0 ± 8.1  years across all 
groups. Mean time between enrolment in the trial and 
death was 20.1 ± 13.6 months.
A summary of data for the cause of death in those with 
type 2 diabetes is shown in Table 2.
HbA1c
Baseline HbA1c was available in 89% of all trial partici-
pants with a mean 62.7 ± 16.4 mmol/mol (7.9%). In those 
with type 2 diabetes, mean HbA1c was 59.7 ± 16.1 mmol/
mol (7.6%), lower than those with type 1 diabetes 
65.8 ± 16.4 mmol/mol (8.2%) (p < 0.01).
Fig. 2 Kaplan Meier survival curves for all‑cause mortality. Participants were followed up for a mean of 42.6 ± 15.6 months. a All individuals in the 
study. b Individuals with type 1 diabetes. c Individuals with type 2 diabetes. The green line denotes participants in the intensive arm of the study, 
the blue line those in the standard arm and the red line the observational arm
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There was no difference in baseline HbA1c in those 
with type 2 diabetes in any of the trial arms. In those with 
type 2 diabetes, mean baseline HbA1c in those whom 
survived till study completion was 63.7 ± 16.4 mmol/mol 
(8.0%) compared with 59.8 ± 16.2  mmol/mol (7.6%) in 
those whom died at any point, a difference that failed to 
reach statistical significance (p = 0.079).
Dropout rate
In the intensive arm of the study, a total of 7 participants 
failed to complete 3 months of the study, of whom 3 died, 
but all attended at least one study visit. No participant 
withdrew consent from any of the three study arms.
Discussion
We and others have previously shown that mortality fol-
lowing severe hypoglycemia in the community is asso-
ciated with high mortality, particularly cardiovascular 
death  [25–27] but studies investigating modulation of 
this adverse clinical outcome are lacking. We present the 
first study that analyses the role of structured nurse-led 
intervention on mortality following severe hypoglycemia 
requiring ambulance services intervention. Over a follow 
up period of approximately 3.5 years, mortality occurred 
in 28% of study population, largely as a result of a high 
death rate in those with type 2 diabetes. In those whom 
received no intervention and had type 2 diabetes, half 
died within the study period, which dropped to a third 
following a simple nurse-led intervention. In contrast, 
nurse-led intervention had no effect on mortality in those 
with type 1 diabetes.
In the type 2 diabetes group, lowest mortality was 
observed in the intervention arm of the study, while 
mortality in the standard and observational arms was 
very similar. Importantly, a reduction in cardiovascu-
lar mortality was demonstrated between the standard 
and intervention study arms whom were well-matched 
at baseline and had an almost identical duration of fol-
low up. Hypoglycemia is particularly detrimental in 
those with type 2 diabetes and clinically established 
cardiovascular disease [28]. However, our analysis sug-
gests that cardiovascular mortality is reduced in the 
intervention arm regardless of the presence of clini-
cally apparent vascular disease at baseline, which may 
indicate that vascular pathology was underdiagnosed in 
our cohort or alternatively the benefits are evident even 
in those with subclinical disease. Of note, type 2 diabe-
tes individuals in the observational arm had the high-
est mortality, which may have been due to the older 
age but numbers are relatively small to draw definitive 
conclusions.
These data emphasise the high death rate in individu-
als with type 2 diabetes and severe hypoglycemia but 
also show that this is potentially modifiable using a rela-
tively simple intervention and regular nurse follow up. It 
should be stressed that individuals in the standard and 
observational arms received support from their health-
care professional according to established guidelines. 
This included a minimum of one patient contact with 
subsequent tailored management according to the need 
of each individual. Therefore, the difference may have 
been even larger in areas where no contact is made when 
patients suffer severe hypoglycemia. The main differences 
between intensive and standard study arms were related 
to: (i) a systematic approach for establishing the cause 
of hypoglycemia and provision of simple education, (ii) 
encouragement to undertake regular glucose testing, 
and (iii) frequent nurse contact for 3 months following 
the hypoglycemic event. The failure to show a survival 
benefit for the nurse-led intervention in individuals with 
type 1 diabetes may be related to the limited number of 
events in this group and lack of adequate power to dem-
onstrate a difference. Alternatively, it may be due to bet-
ter hypoglycemic knowledge in this population with the 
Table 2 A summary of cause of death in those with type 2 diabetes
Cardiovascular death was the leading cause of fatality which was reduced with nurse led intervention in those with type 2 diabetes
Numbers in italics signify statistically significant differences
Death from Intensive (n = 60) Standard (n = 64) Observation 
(n = 36)
Test of difference: 
intensive vs. standard
Test of difference: 
intensive vs. 
combined
Cardiovascular cause (%) 1 (1.7) 12 (18.8) 11 (30.6) p = 0.002 p ≤ 0.001
Infection (%) 7 (11.7) 9 (14.1) 3 (8.3) p = 0.69 p = 0.95
Renal disease (%) 3 (5) 0 (0) 0 (0) p = 0.11 p = 0.05
Old age/dementia/cancer (%) 4 (6.7) 6 (9.4) 2 (5.6) p = 0.75 p = 1.0
Glycaemic emergency (%) 0 (0) 0 (0) 0 (0) NA NA
Other/unknown cause (%) 5 (8.3) 5 (7.8) 3 (8.3) p = 1.0 p = 1.0
Total (%) 20 (33.3) 32 (50) 19 (52.8) p = 0.056 p = 0.025
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nurse support having little additional benefit. It is also 
possible that the type 1 diabetes group had less extensive 
vascular disease, which limited the detrimental effect of 
hypoglycemia.
A striking observation is the continued drop in mortal-
ity beyond the period of nurse intervention, suggesting 
that a short period of structured nurse support is enough 
to reduce long-term mortality in the type 2 diabetes 
group.
HbA1c was lower at baseline in individuals with type 
2 diabetes compared to those with type 1 diabetes, indi-
cating that hypoglycemia requiring ambulance services 
intervention occurs with higher average glucose con-
trol in those with type 1 diabetes. Moreover, there was a 
numerical inverse relationship between baseline HbA1c 
and mortality in type 2 diabetes suggesting that tight gly-
caemic control in the older population is best avoided.
When investigating the cause of death in type 2 diabe-
tes individuals, cardiovascular disease was the common-
est cause followed by infections. Post-hoc analysis of the 
Veterans Affairs Diabetes Trial [29] also found increased 
risk of cardiovascular events in those whom had suf-
fered an episode of severe hypoglycemia in the previous 
3 months and these findings are consistent with reports 
from other large-scale trials  [12]. Interestingly, reduc-
tion in mortality was mainly due to lower cardiovascular 
events in the intensive nurse-led arm of the study, while 
having no effects on other causes of death. Of note, the 
main role of the nurse was to focus on optimising glycae-
mic control, while avoiding interference with the man-
agement of other vascular risk factors. Therefore, the 
difference in mortality comparing study arms is likely 
related to glycemic factors, although patient-related 
behavioural changes (such as decreased alcohol con-
sumption) may have also played a role.
The work has a number of strengths to highlight. First, 
no interventional study to date has investigated modula-
tion of outcome in individuals with severe hypoglycemia 
requiring emergency services intervention. Second, indi-
viduals were well characterised, including classification 
into type 1 diabetes and type 2 diabetes, while the cause 
of death was clearly established. Third, median study fol-
low up extended to over 3  years with an effect for the 
intervention shown well beyond the period of intensive 
nurse support. Fourth, retention in the study was high, 
indicating that the intervention is acceptable and con-
venient to patients, and therefore can be rolled out to the 
wider population.
There are a number of limitations to the study that 
should be acknowledged. First, more than half the 
patients approached declined to participate in the 
study or failed to attend study appointment, and there-
fore a significant proportion of patients may not wish 
to undergo such a nurse-led intervention. Second, this 
was a pilot study covering one geographical area and the 
number of individuals in each study arm was relatively 
small. In particular, mortality in individuals with type 1 
diabetes was low and therefore no concrete conclusions 
can be drawn in this group. Third, the main focus of the 
intervention was to provide education to participants 
and encourage regular glucose testing; therefore the 
exact details of changes to patient medications, includ-
ing insulin, were not systematically recorded. As a result, 
we are unable to report on changes in total daily insu-
lin doses or alterations to oral hypoglycemic agents or 
indeed the effect of the intervention on reducing fur-
ther hypoglycemic episodes. This will require assess-
ment in future large scale trials, perhaps with the aid 
of continuous glucose monitoring to accurately study 
hypoglycemic exposure in study arms. Fourth, unlike 
the interventional and standard study arms that were 
well-matched, there were some differences in baseline 
patient characteristics in the observational arm. There-
fore, we should be cautious in our interpretation when 
comparing interventional with the combined standard 
and observational groups. However, the interventional 
arm consistently showed lower mortality, whether com-
pared with the combined group or the standard group, 
strongly suggesting a beneficial effect of the intervention 
on survival. Fifth, we do not provide mechanistic expla-
nations for the apparent survival benefit of the inter-
vention, although modulation of hypoglycemia and/or 
glycemic variability may have contributed to the benefi-
cial vascular effect [30] but data on these glycemic vari-
ables were not collected. Finally, it was not possible to 
blind participants to study arms, given the nature of the 
work, and therefore the role of altered patient behaviour 
to study outcome remains unclear.
In summary, this pilot study raises the exciting pos-
sibility that short-term intensive nurse led intervention 
can reduce cardiovascular mortality in a high-risk group 
of individuals with type 2 diabetes following an episode 
of hypoglycemia requiring ambulance call out. Further 
large-scale trials, focussed on individuals with type 2 
diabetes, are warranted to confirm results and assess 
the cost effectiveness of such an approach. Also, future 
studies should collect data on changes to hypoglycemic 
medications, including alterations to insulin type or dose, 
as well as substitution of oral treatment with agents that 
have low risk of hypoglycemia. This is particularly rel-
evant given recent data showing that sodium-glucose 
transport protein-2 inhibitors and glucagon-like pep-
tide-1 analogues are associated with favourable car-
diovascular outcome, which may further contribute to 
reduction in vascular events, the main cause of mortality 
in this population.
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Conclusions and further work
This pilot study extends previous findings that severe 
hypoglycemia in the community represents significant 
danger to those with type 2 diabetes with a particularly 
concerning high rate of cardiovascular death over a short 
to medium follow up period. This work suggests that 
this increased risk is potentially modifiable with inten-
sive nurse led intervention and further larger trials are 
required to investigate generalisability of our findings to 
different healthcare models.
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